Product Information
BIIB-024 is a monoclonal antibody that targets mutant melanoma cells. It binds to the tumor and prevents it from growing, as well as preventing the cancer cells from spreading. BIIB-024 has shown effectiveness in clinical studies by reducing tumor size and skin reactions in patients with melanoma. The effective dose of BIIB-024 is 10 milligrams per kilogram of body weight. BIIB-024 also inhibits protein synthesis in tumor cells, which may be due to its ability to bind to cytosolic proteins.
Chemical properties
Technical inquiry about: 3D-FB103923 BIIB-024
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
